Abstract
Glioblastoma is an aggressive primary tumor of the central nervous system. This review will focus on clinical developments and management of newly diagnosed disease, including a discussion about the incorporation of molecular features into the classifi cation of glioblastoma. Such advances will continue to shape our thinking about the disease and how to best manage it. With regards to treatment, the role of surgical resection, radiotherapy, chemotherapy, and tumortreating fi elds will be presented. Pivotal studies defi ning our current standard of care will be highlighted, as will key ongoing trials that may infl uence our management of glioblastoma in the near future.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 91-100 |
| Number of pages | 10 |
| Journal | Oncology (United States) |
| Volume | 33 |
| Issue number | 3 |
| State | Published - 2019 |
Funding
Wainwright, Dr. Sonabend, and Dr. Stupp receive funding support from P50CA221747 SPORE for Translational Approaches to Brain Tumors. Dr. Lukas is a consultant for AbbVie, and has served as a consultant for NewLink Genetics and ReNeuron; he has also served on an advisory board for Monteris Medical; served as a medical editor for EBSCO and MedLink Neurology; and has presented CME board review courses for the American Physician Institute. Dr. Wainwright receives funding support from the NIH/National Institute of Neurological Disorders and Stroke R01NS097851 grant. Dr. Sonabend is a consultant for AbbVie. Dr. Stupp receives travel support from NovoCure; he also served on one-time advisory boards for Boehringer Ingelheim, Celgene, and Northwest Biotherapeutics. Dr. Ladomersky and Dr. Sachdev have no significant financial interest in or other relationship with the manufacturer of any product or provider of any service mentioned in this article.
ASJC Scopus subject areas
- Oncology
- Cancer Research
